ATE217523T1 - Loteprednoletabonat-suspension - Google Patents

Loteprednoletabonat-suspension

Info

Publication number
ATE217523T1
ATE217523T1 AT94930831T AT94930831T ATE217523T1 AT E217523 T1 ATE217523 T1 AT E217523T1 AT 94930831 T AT94930831 T AT 94930831T AT 94930831 T AT94930831 T AT 94930831T AT E217523 T1 ATE217523 T1 AT E217523T1
Authority
AT
Austria
Prior art keywords
suspension
loteprednoletabonate
steroid drugs
water
insoluble steroid
Prior art date
Application number
AT94930831T
Other languages
English (en)
Inventor
Yaacov J Guy
Doron Friedman
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Application granted granted Critical
Publication of ATE217523T1 publication Critical patent/ATE217523T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Resins (AREA)
  • Steroid Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Adhesives Or Adhesive Processes (AREA)
AT94930831T 1993-10-25 1994-10-21 Loteprednoletabonat-suspension ATE217523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment
PCT/US1994/012059 WO1995011669A1 (en) 1993-10-25 1994-10-21 Suspension of loteprednol etabonate

Publications (1)

Publication Number Publication Date
ATE217523T1 true ATE217523T1 (de) 2002-06-15

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930831T ATE217523T1 (de) 1993-10-25 1994-10-21 Loteprednoletabonat-suspension

Country Status (17)

Country Link
US (2) US5540930A (de)
EP (1) EP0730443B1 (de)
JP (1) JP3570720B2 (de)
KR (1) KR100341497B1 (de)
AT (1) ATE217523T1 (de)
AU (1) AU697617B2 (de)
BR (1) BR9407958A (de)
CA (1) CA2174550C (de)
DE (1) DE69430635T2 (de)
DK (1) DK0730443T3 (de)
ES (1) ES2179851T3 (de)
HU (1) HU227316B1 (de)
IL (1) IL111402A (de)
NZ (1) NZ275749A (de)
PT (1) PT730443E (de)
SG (1) SG48768A1 (de)
WO (1) WO1995011669A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
CN1158995C (zh) * 1998-01-22 2004-07-28 参天制药株式会社 氟米龙眼用混悬液
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
JP2002523475A (ja) * 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE50001217D1 (de) * 1999-06-22 2003-03-13 Boehringer Ingelheim Int Stabile xylometazolin- und oxymetazolinlösung
FR2796553B1 (fr) * 1999-07-22 2001-09-28 Warner Lambert Co Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
EP1214056B1 (de) 1999-09-24 2003-10-29 Alcon Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
EP1142565A4 (de) * 1999-10-20 2004-03-17 Teijin Ltd Wässerige arzneimittel
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
CN1376066A (zh) * 1999-11-18 2002-10-23 爱尔康公司 H1拮抗剂和安全类固醇的治疗眼病的用途
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2001276928A1 (en) 2000-07-26 2002-02-05 Alcon Universal Ltd. Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
EP1337237B1 (de) * 2000-11-15 2009-03-11 Mohan A. Chandavarkar Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
AU1770901A (en) * 2000-11-16 2002-05-27 Alcon Lab Inc Combination therapy for lowering and controlling intraocular pressure
ATE313328T1 (de) 2001-09-21 2006-01-15 Alcon Inc Verfahren zur behandlung von mittelohrinfektionen
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US7727549B2 (en) * 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
ES2314284T3 (es) * 2002-10-18 2009-03-16 Aqueous Pharma Limited Formulacion lagrimal de tres capas.
EP1572216A1 (de) * 2002-12-20 2005-09-14 Control Delivery Systems, Inc. Steroid-zusammensetzungen zur intraokularen anwendung
EP1586316B1 (de) 2003-01-21 2008-04-30 Senju Pharmaceutical Co., Ltd. Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20090246281A1 (en) * 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20080306039A1 (en) * 2003-12-02 2008-12-11 Keiichi Matsuhisa Loteprednol Etabonate Aqueous Suspension
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
CA2553381C (en) * 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
JP2007530573A (ja) 2004-03-25 2007-11-01 ボーシュ アンド ローム インコーポレイティド ドライアイの治療にロテプレドノールエタボネートを使用すること
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
BRPI0513243B8 (pt) * 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
CA2580659C (en) * 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
PT1906916E (pt) * 2005-05-10 2008-12-10 Alcon Inc Suspensão oftálmica compreendendo um fármaco oftálmico, uma poloxamina e um agente de ajuste da tonicidade de glicol, utilização da referida composição para a produção de um medicamento para o tratamento de distúrbios oftálmicos
DK1885336T3 (da) * 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
CN101272772A (zh) * 2005-09-26 2008-09-24 皮埃蒙特医药品有限公司 使用化学渗透促进剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
CA2622002A1 (en) * 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
MX339797B (es) 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
MX2008012495A (es) 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
EP2089035A1 (de) * 2006-11-02 2009-08-19 Riolan Technologies, Inc. Verfahren zur behandlung von blepharitis
US20080119448A1 (en) * 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
EP2538929A4 (de) 2010-02-25 2014-07-09 Univ Johns Hopkins Verzögerte freisetzung von therapiemitteln in einen teil des auges
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP3045163A1 (de) * 2011-04-22 2016-07-20 Alcon Research, Ltd. Ophthalmische zusammensetzung mit einem viskositätsverstärkungssystem mit zwei unterschiedlichen viskositätsverstärkern
SG10201610097WA (en) 2011-08-18 2017-01-27 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013043387A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
CN104363924B (zh) 2012-03-16 2018-04-17 约翰霍普金斯大学 用于递送hif‑1抑制剂的控制释放调配物
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR20150006869A (ko) * 2012-05-03 2015-01-19 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
CN103565742A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 氟米龙滴眼液
CN103565740A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 依碳氯替泼诺混悬滴眼液
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
ES2912327T3 (es) * 2014-11-07 2022-05-25 Santen Pharmaceutical Co Ltd Composición acuosa oftálmica
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
US12023344B2 (en) 2022-05-25 2024-07-02 Famygen Life Sciences, Inc. Topical otic, ophthalmic, and nasal corticosteroid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS6041607A (ja) * 1983-08-12 1985-03-05 Otsuka Pharmaceut Co Ltd 軟膏基剤
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
CA2174550A1 (en) 1995-05-04
HU9601081D0 (en) 1996-06-28
SG48768A1 (en) 1998-05-18
JP3570720B2 (ja) 2004-09-29
NZ275749A (en) 1998-02-26
JPH09504294A (ja) 1997-04-28
EP0730443A4 (de) 1997-11-05
BR9407958A (pt) 1996-11-26
HU227316B1 (en) 2011-03-28
DK0730443T3 (da) 2002-09-09
EP0730443A1 (de) 1996-09-11
EP0730443B1 (de) 2002-05-15
KR100341497B1 (ko) 2002-12-05
DE69430635T2 (de) 2003-01-02
WO1995011669A1 (en) 1995-05-04
DE69430635D1 (de) 2002-06-20
HUT74882A (en) 1997-02-28
IL111402A0 (en) 1994-12-29
AU7983594A (en) 1995-05-22
US5747061A (en) 1998-05-05
ES2179851T3 (es) 2003-02-01
IL111402A (en) 2000-12-06
US5540930A (en) 1996-07-30
KR960705541A (ko) 1996-11-08
PT730443E (pt) 2002-11-29
AU697617B2 (en) 1998-10-15
CA2174550C (en) 2002-10-01

Similar Documents

Publication Publication Date Title
ATE217523T1 (de) Loteprednoletabonat-suspension
AU7655194A (en) Active principles and gas containing microparticles
DE69605417D1 (de) Formulierungen zum suspendieren: von proteine und peptiden
DE60226613D1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
ES488888A1 (es) Procedimiento de fabricacion de una suspension acuosa de alumina
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
AU5309794A (en) Pharmaceutical compositions containing nanocapsules
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
BR9809865A (pt) Fixador de perfume, perfume e produto base misturados com o mesmo, e, produto perfumado.
FI945081A0 (fi) Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon
ID28780A (id) Komposisi granul
ATE286941T1 (de) Wässrige bindemitteldispersionen, überzugsmittel und deren verwendung
IL113178A (en) 8alpha-3-hydroxyestra-1,3,5(11)tetraen-17-one( 9(11)-dehydro-8-isoestrone) its preparation and pharmaceutical composition containing it
IL87623A (en) Compositions containing biosynthetic pesticide products and 1,2-benzisothiazolin-3-one as stabilizer, their production and their use
AU6893994A (en) Pharmaceutical compositions
PT1453380E (pt) Composicoes contendo sacarido e silica hidrofobica
PL308838A1 (en) Pharmaceutical preparation containing cefixim as its active substance and method of stabilising such preparations
BG103306A (en) Liquid allendronate compositions
ATE37185T1 (de) Kontrazeptive zusammensetzungen auf basis von levo-norgestrel-estern.
TW218011B (de)
BG104133A (bg) Метод за получаване на невирапин хемихидрат и фармацевтичен състав, който го съдържа
IT8785532A0 (it) Distaccanti per il ripristino degli organi di sospensione usati nella verniciatura industriale.
AR002256A1 (es) Composicion anti-inflamatoria, util para uso oftamologico y otorilaringologico

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification